Medifast, Inc.

Informe acción NYSE:MED

Capitalización de mercado: US$267.4m

Medifast Dirección

Dirección controles de criterios 3/4

El CEO de Medifast's es Dan Chard , nombrado en Oct 2016, tiene una permanencia de 7.5 años. compensación anual total es $5.94M, compuesta por 16.5% salario y 83.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.38% de las acciones de la empresa, por valor de $4.99M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 7.5 años, respectivamente.

Información clave

Dan Chard

Chief Executive Officer (CEO)

US$7.0m

Compensación total

Porcentaje del salario del CEO14.2%
Permanencia del CEO7.6yrs
Participación del CEO1.4%
Permanencia media de la dirección4.2yrs
Promedio de permanencia en la Junta Directiva7.6yrs

Actualizaciones recientes de la dirección

Recent updates

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

Medifast: Cheap Valuation, Uncertain Future

Mar 20

Medifast Is Getting Attractive

Mar 07

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Feb 22
Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Jan 20

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Dec 09
Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Nov 24

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Nov 21
Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Nov 09

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Oct 09

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Aug 04

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Jul 26
Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Jul 21

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Jul 05
Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast: In Survival Mode Against Diet Pills And The Recession

Jun 14

Medifast Holds Value During Headwinds

May 28

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Feb 21

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

Feb 07

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Jan 19
At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Medifast declares $1.64 dividend

Dec 08

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Dec 01
A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 10
Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems

One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Nov 08
One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates

Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy

Nov 06

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Oct 20
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Sep 18
We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt

Medifast declares $1.64 dividend

Sep 08

Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Sep 02
Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?

Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good

Aug 21

Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Aug 09
Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year

Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

Jul 27
Are Medifast, Inc. (NYSE:MED) Investors Paying Above The Intrinsic Value?

What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Jul 12
What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?

Medifast And Its Real Value

Jun 24

Medifast: Growth And Value At A Reasonable Price

May 17

Here's Why I Think Medifast (NYSE:MED) Might Deserve Your Attention Today

May 03
Here's Why I Think Medifast (NYSE:MED) Might Deserve Your Attention Today

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Chard en comparación con los beneficios de Medifast?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

US$68m

Dec 31 2023US$7mUS$1m

US$99m

Sep 30 2023n/an/a

US$120m

Jun 30 2023n/an/a

US$133m

Mar 31 2023n/an/a

US$142m

Dec 31 2022US$6mUS$981k

US$144m

Sep 30 2022n/an/a

US$151m

Jun 30 2022n/an/a

US$157m

Mar 31 2022n/an/a

US$165m

Dec 31 2021US$7mUS$914k

US$164m

Sep 30 2021n/an/a

US$158m

Jun 30 2021n/an/a

US$150m

Mar 31 2021n/an/a

US$125m

Dec 31 2020US$6mUS$909k

US$103m

Sep 30 2020n/an/a

US$95m

Jun 30 2020n/an/a

US$76m

Mar 31 2020n/an/a

US$76m

Dec 31 2019US$5mUS$843k

US$78m

Sep 30 2019n/an/a

US$74m

Jun 30 2019n/an/a

US$72m

Mar 31 2019n/an/a

US$64m

Dec 31 2018US$2mUS$675k

US$56m

Sep 30 2018n/an/a

US$47m

Jun 30 2018n/an/a

US$40m

Mar 31 2018n/an/a

US$34m

Dec 31 2017US$2mUS$650k

US$28m

Compensación vs. Mercado: La compensación total de Dan($USD5.94M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan Chard (58 yo)

7.6yrs

Permanencia

US$7,039,062

Compensación

Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Chard
Executive Chairman & CEO7.6yrsUS$7.04m1.4%
$ 3.7m
James Maloney
Chief Financial Officer3.8yrsUS$2.01m0.069%
$ 183.5k
Anthony Tyree
Chief Business Operations Officer2.3yrsUS$1.61m0.074%
$ 197.0k
Jason Groves
Executive VP12.5yrsUS$1.63m0.073%
$ 196.3k
Nicholas Johnson
Chief Field Operations Officer5.3yrsUS$1.70m0.061%
$ 164.4k
Jonathan MacKenzie
VP of Finance & Chief Accounting Officer2.7yrssin datos0.0050%
$ 13.2k
Steven Zenker
Vice President of Investor Relations1.2yrssin datossin datos
Claudia Greninger
Chief Human Resources Officer4.6yrssin datossin datos

4.2yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MED se considera experimentado (4.1 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Daniel Chard
Executive Chairman & CEO7.6yrsUS$7.04m1.4%
$ 3.7m
Jeffrey Brown
Lead Independent Director8.9yrsUS$263.42k0.063%
$ 168.2k
George Bray
Member of Scientific Advisory Boardno datasin datossin datos
Michael Hoer
Independent Director5.9yrsUS$249.72k0.049%
$ 131.4k
Andrea Thomas
Independent Director4.9yrsUS$249.72k0.029%
$ 78.4k
John Foreyt
Member of Scientific Advisory Boardno datasin datossin datos
Ming Xian
Independent Director5.9yrsUS$219.61ksin datos
Lawrence Cheskin
Chairman of Scientific Advisory Board15.5yrssin datossin datos
Sylvia Rowe
Member of Scientific Advisory Boardno datasin datossin datos
Scott Schlackman
Independent Director8.9yrsUS$252.44k0.043%
$ 115.8k
John Hayes
Member of Scientific Advisory Boardno datasin datossin datos
Mark Messina
Member of Scientific Advisory Boardno datasin datossin datos

7.6yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de MED se considera experimentada (7.5 años de antigüedad promedio).